CEO and founder Rachel McMinn outlined the company’s progress toward a potential commercial launch for its lead gene therapy ...

Navigator models, particularly cross-specialty nurse navigation, reduce stress, expedite diagnosis-to-treatment transitions, and support participation in trials designed around transportation, work ...

AI search ads are seen as having massive potential by ad industry insiders and analysts, but OpenAI rival Anthropic has ...

BlueRock Therapeutics, a Bayer subsidiary developing stem cell treatments for Parkinson’s disease, has partnered with Rune ...

The ex-WWE star who was accused of using federal funds earmarked to social services for “needy families” to pay for his luxury lifestyle, including buying a million-dollar home, was found not guilty ...

Retatrutide demonstrated promising results in its first late-stage trial for Type 2 Diabetes, reducing HbA1c levels by up to ...

Five people who were charged in connection to the Feeding Our Future​ scheme pleaded guilty to wire fraud this week.

A former professional wrestler accused of misspending millions of welfare dollars in part of Mississippi’s largest public corruption scandal has been found not guilty by a jury ...

Gilead HPI licensing adds $35M now + $330M milestones; Phase 2 starts by 2026; strong cash runway. Click for this ASMB update ...

Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...

The murder that Christa Pike was convicted of demonstrated a brutality and callousness not often seen in women, let alone one ...

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of ...